Zambon Pharma

Our daily commitment: improving patients’ lives

CEO message

Roberto Tascione

"We keep strengthening our pipeline and building a better future for our patients and their families, while delivering a great performance for the company".

Roberto Tascione, CEO Zambon S.p.A.

Our focus

The company today has a strong focus on the treatment of rare respiratory and CNS diseases, as well as cough and cold, women’s care and pain management.
Severe respiratory diseases
Severe respiratory diseases

Zambon is continually searching for solutions to improve the lives of patients affected by severe respiratory diseases such as CF, BOS and NCFB. 

Show more
Cough and cold
DISEASES OF THE RESPIRATORY SYSTEM

We have developed a wide range of treatment solutions for the most prevalent respiratory diseases.

Show more
Pain
Pain

We have developed a formula dedicated to treating moderate pain.

Show more
Parkinson
NEUROLOGICAL DISORDERS

In the coming years, we will continue to invest in research aimed at improving the quality of life of Parkinson's patients.

Show more
Women's health
UROLOGICAL SYSTEM

We develop solutions that help treat simple infections of the urinary tract.

Show more
Open R&D

Open R&D

We continue to show significant progress in Research&Development, successfully reinforcing our collaborations with scientific communities and patient groups around the world.

Plants

Industrial Business Operations

Our plants in Italy, Switzerland, China and Brazil utilize consistent approach worldwide, delivering high-quality standardized products and using state of the art technological operations.

BD

Business Development

Zambon Business Development remains focused on early and late stage assets in our strategic Therapeutic Areas: CNS and Severe Respiratory Diseases.

ZLIFE

Z-LIFE

Designed from the ruins of the previous industrial building, Z-LIFE the new home of Zambon Pharma, was created within the OpenZone campus to promote our approach based on sharing without boundaries and on our ability to transform ideas into tangible opportunities for patients.

GS

Growth Strategy

Our growth will be driven by increasing further internationalization, maximizing our core products and gradually expand our focus on specialties like Parkinson’s Disease, BOS and NCFB.

724

Million euros in revenues

Year 2019
2,533

People around the world

Year 2019
63

Million Euros Net Income

Year 2019